Literature DB >> 8187248

Lp(a) lipoprotein: an overview.

K Berg1.   

Abstract

The Lp(a) lipoprotein, a distinct class of serum lipoproteins, was detected in 1962. It consists of an LDL particle to which a long polypeptide chain is attached by a disulfide bridge. The level of Lp(a) lipoprotein is genetically determined. Single locus control was suggested already in the very first report, and this has been conclusively confirmed by the demonstration of absolute genetic linkage to the plasminogen gene, from which the LPA gene is likely to have evolved. The detection in 1974 of an association between Lp(a) lipoprotein and coronary heart disease has been confirmed in numerous studies. The Lp(a) lipoprotein may have atherogenic as well as thrombogenic properties and thus form the bridge between atherogenesis and thrombogenesis. Genes determining a moderate level of Lp(a) lipoprotein may be longevity genes, and it seems possible that Lp(a) lipoprotein, because of its affinity to vessel walls, may also influence placental function. Lp(a) lipoprotein measurements should be included in the diagnostic work-up of people with premature coronary heart disease or with such disease in close relatives.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187248     DOI: 10.1016/0009-3084(94)90119-8

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  8 in total

Review 1.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 2.  The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events.

Authors:  A M Scanu
Journal:  Curr Cardiol Rep       Date:  2001-09       Impact factor: 2.931

3.  Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes.

Authors:  J D Zampoulakis; A A Kyriakousi; K A Poralis; N T Karaminas; I D Palermos; E T Chimonas; D V Cokkinos
Journal:  Clin Cardiol       Date:  2000-12       Impact factor: 2.882

Review 4.  Effects of exercise on lipoprotein(a).

Authors:  L T Mackinnon; L M Hubinger
Journal:  Sports Med       Date:  1999-07       Impact factor: 11.136

5.  The heritability of human longevity: a population-based study of 2872 Danish twin pairs born 1870-1900.

Authors:  A M Herskind; M McGue; N V Holm; T I Sørensen; B Harvald; J W Vaupel
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

6.  Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study.

Authors:  Dov Shiffman; Ellen S O'Meara; Lance A Bare; Charles M Rowland; Judy Z Louie; Andre R Arellano; Thomas Lumley; Kenneth Rice; Olga Iakoubova; May M Luke; Bradford A Young; Mary J Malloy; John P Kane; Stephen G Ellis; Russell P Tracy; James J Devlin; Bruce M Psaty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-11-01       Impact factor: 8.311

7.  Performance evaluation of five lipoprotein(a) immunoassays on the Roche cobas c501 chemistry analyzer.

Authors:  Sara P Wyness; Jonathan R Genzen
Journal:  Pract Lab Med       Date:  2021-03-24

8.  Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank.

Authors:  Sean J Jurgens; Seung Hoan Choi; Valerie N Morrill; Mark Chaffin; James P Pirruccello; Jennifer L Halford; Lu-Chen Weng; Victor Nauffal; Carolina Roselli; Amelia W Hall; Matthew T Oetjens; Braxton Lagerman; David P vanMaanen; Krishna G Aragam; Kathryn L Lunetta; Christopher M Haggerty; Steven A Lubitz; Patrick T Ellinor
Journal:  Nat Genet       Date:  2022-02-17       Impact factor: 41.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.